COPD Management Guidelines

Diagnostic Standards

The American Thoracic Society recommends that spirometry is the essential diagnostic tool and must be performed in all suspected COPD cases, as the diagnosis cannot be made without objective spirometric confirmation 1, 2
Post-bronchodilator testing is mandatory, with spirometry repeated after bronchodilator administration to confirm persistent airflow limitation and rule out asthma 1
Repeat spirometry is recommended for patients with initial FEV1/FVC ratios between 0.6-0.8 to account for day-to-day variability and increase diagnostic specificity 1
A positive bronchodilator response is defined as FEV1 increase of ≥200 mL AND ≥15% from baseline, which suggests possible asthma rather than pure COPD 3, 4
Chest radiography excludes other pathologies but cannot positively diagnose COPD, though it may identify bullae in some patients 3, 4
Arterial blood gas measurement is necessary in severe COPD to identify patients with persistent hypoxemia (low oxygen levels) with or without hypercapnia (elevated carbon dioxide levels) 3, 4

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that short-acting bronchodilators used as needed are the gold standard for mild, symptomatic COPD 3, 4, 2
Long-acting bronchodilator monotherapy is the gold standard first-line treatment for moderate COPD with daily symptoms, with long-acting muscarinic antagonists (LAMAs) preferred over LABAs for exacerbation prevention 5, 2
A corticosteroid trial should be considered in all moderate COPD patients, with 30 mg prednisolone daily for 2 weeks and pre- and post-spirometry, as objective improvement occurs in only 10-20% of cases 3, 4, 2
Combination LABA/LAMA therapy is the gold standard for severe COPD, as it provides superior symptom control and exacerbation prevention compared to monotherapy 5, 2
Triple therapy (LABA/LAMA/ICS) should be reserved for patients with severe disease and frequent exacerbations or asthma-COPD overlap 2
Long-term ICS monotherapy is not recommended and should only be used in combination with LABAs 5, 2

The American College of Chest Physicians recommends that smoking cessation is the single most important intervention at all disease stages, and is the only treatment proven to prevent accelerated lung function decline 3, 4, 2
Pulmonary rehabilitation is the gold standard for moderate to severe COPD, including physiotherapy, muscle training, nutritional support, and education, as it improves exercise tolerance, reduces breathlessness, and enhances quality of life 3, 4, 2
Annual influenza vaccination is recommended for all COPD patients, especially those with moderate to severe disease, and pneumococcal vaccination should be considered with revaccination every 5-10 years 3, 4, 2

The European Respiratory Society recommends that long-term oxygen therapy (LTOT) is the gold standard for hypoxemic COPD patients with low oxygen levels, as it prolongs life, with the goal of maintaining oxygen saturation ≥90% during rest, sleep, and exertion 3, 4, 2
Oxygen concentrators are the preferred delivery method for home use, and LTOT should only be prescribed with objectively demonstrated hypoxemia or high cylinder use 2, 3, 4

Beta-blocking agents must be avoided in COPD patients, as they can worsen symptoms 2
Theophyllines are of limited value in routine COPD management and should be reserved as third-line therapy 3, 4, 2
There is no role for other anti-inflammatory drugs beyond ICS in COPD management, and prophylactic antibiotics given continuously or intermittently are not recommended for stable COPD 3, 4, 2
Subjective improvement alone is not a satisfactory endpoint for corticosteroid trials, and objective spirometric improvement is required 3, 4, 2

Inhaler technique must be demonstrated before prescribing and checked regularly, as many COPD patients make critical errors with inhalers, and an appropriate device should be selected to ensure efficient delivery 2, 3, 4
Patients should rinse their mouth with water without swallowing after inhalation to reduce the risk of oropharyngeal candidiasis 3, 4, 2